ReviewBreathe (Sheffield, England)2020
Lymphangioleiomyomatosis: a clinical review.
Review in Breathe (Sheffield, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Stromal-only endometriosis catamenial pneumothorax: A diagnostic algorithm with potential pitfalls.Virchows Archiv : an international journal of pathology · 2026Article
- High prevalence of TSC2 mutations in lung tissue samples from patients with sporadic lymphangioleiomyomatosis.The European respiratory journal · 2026Article
- Diagnostic Value of Serum VEGF-D in Lymphangioleiomyomatosis: Results of the First Prospective Study in the Russian Federation.Diagnostics (Basel, Switzerland) · 2026Article
- Sporadic lymphangioleiomyomatosis with lymphocyte-predominant pleural effusion misdiagnosed as tuberculosis: a case report.Respiratory medicine case reports · 2026Article
- Clinical characteristics and molecular genetic analysis of 73 cases of tuberous sclerosis complex caused byFrontiers in pediatrics · 2026Article
- Artificial Intelligence Enabled Lung Sound Auscultation in the Early Diagnosis and Subtyping of Interstitial Lung Disease.Journal of clinical medicine · 2025Review
- Loss of tuberous sclerosis complex 2 confers inflammation via dysregulation of nuclear factor kappa-light-chain-enhancer of activated B cells.Journal of inflammation (London, England) · 2025Article
- Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry.International journal of molecular sciences · 2025Article
- Diagnostic Challenges in Lymphangioleiomyomatosis: From Ovarian Mass to Systemic Diagnosis.Acta medica Lituanic · 2025Article
- Article
- Uterine lymphangioleiomyomatosis in a premenopausal woman with tuberous sclerosis: A case report.Case reports in women's health · 2024Article
- Clinical, tomographic and functional comparison of sporadic and tuberous sclerosis complex-associated forms of lymphangioleiomyomatosis: a retrospective cohort study.ERJ open research · 2024Article
- Tuberous sclerosis-associated pulmonary lymphangioleiomyomatosis: The role of pulmonary rehabilitation - A case report.Respiratory medicine case reports · 2024Article
- Lymphangioleiomyomatosis with Tuberous Sclerosis Complex-A Case Study.Journal of personalized medicine · 2023Article
- Article
- Pulmonary benign metastasizing uterine leiomyoma (PBML): a case report and review of the literature.Annals of medicine and surgery (2012) · 2023Article
- Cystic Lung Disease Presenting as Recurrent Non-traumatic Chylothorax: Case Report and a Mini-Review.Cureus · 2023Article
- An Evidence-Based Update on the Potential Association between Rheumatoid Arthritis and Lymphangioleiomyomatosis.Journal of personalized medicine · 2023Review
- Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphangioleiomyomatosis (LAM) is a diffuse cystic lung disease. There are two main types of LAM: sporadic, and LAM associated with the tuberous sclerosis complex (TSC), which is caused by mutations in the EDUCATIONAL
aimsTo illustrate the clinical features, common presentations and radiological features of LAMTo outline the diagnostic approach to LAM, including the role of VEGF-DTo review the current prognostic indicators in LAM, and outline the impact of lung function, hormonal status, VEGF-D and clinical presentation on outcomeTo inform clinicians on the management options for LAM both pharmacological and nonpharmacological.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.